HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].

AuthorsE Heidemann
JournalStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Strahlenther Onkol) Vol. 174 Issue 5 Pg. 290-1 (May 1998) ISSN: 0179-7158 [Print] Germany
Vernacular TitleKein Vorteil durch zusätzliche CMF-Behandlung bei nodal positivem, postmenopausalem, Rezeptor-positivem Mammakarzinom unter adjuvanter Tamoxifen-Therapie.
PMID9614963 (Publication Type: Journal Article, Review)
Chemical References
  • Tamoxifen
  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Chemotherapy, Adjuvant
  • Cyclophosphamide (administration & dosage)
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Lymphatic Metastasis
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Postmenopause
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Tamoxifen (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: